Gepotidacin

吉珀达星

Report date: 2026/04/29 20:02:18
NMEFirst In ClassQIDP

Base Information

Drug NameGepotidacin
Drug Alias Name吉泊达星GepotidacinumGepotidacinaBlujepaGSK-2140944 +[7] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsUrinary Tract InfectionsRespiratory Tract InfectionsGonorrhea +[4] 
Global Approved IndicationsUrinary Tract Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/03/25
Country/TerritoryCzechiaBulgariaUnited States +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Santé Et De La Recherche Médicale, France U979Glaxosmithkline Trading Services LtdGlaxosmithkline Plc +[5] 
Inactive CompaniesN/A
Active IndicationsUrinary Tract InfectionsGonorrheaBacterial Infections
Inactive IndicationsRespiratory Tract Infections

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG